CYTOTERRA INC.

SEATTLE, WA · Founded 2025 · Biotech · Private

CytoTerra Plus, a high-throughput genomic integrity platform combining Genomic Proximity Mapping and whole exome sequencing to detect structural variants and single nucleotide variants in allogeneic c

Claim this profile

Follows are private to you and power your alerts

Updated · cytoterra.com

Sector
Biotech
Headquarters
SEATTLE, WA
Founded
2025
Latest Form D
$300K, Oct 2026
Total capital
$2.3M
Federal grants
$958K
1 award · 2026
Rank in peer group#32 of 37
Private capital raised
$1.3M
2 Form D · last Oct 2026
1 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
1 pending

Capital timeline

2026FEDERAL ↑EQUITY ↓Cumulative $2.3M$958K1st Form D$1M2nd Form D$300K
2026FEDERAL ↑EQUITY ↓Cumulative $2.3M$958K1st Form D$1M2nd Form D$300K

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$300K
  • Federal grantHealth and Human S · Phase II · Comprehensive Genomic Integrity Assessment for Allogenic Cell Therapies using Genomic proximity mapping$958K
  • Private capital raisedForm D · SEC · 1st filing$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 37 peers

Line = median

Biotech · Platform

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Jesse SalkDirectorNamed in SEC Form D filings
  • Sean MacLeodDirectorNamed in SEC Form D filings
  • Stephen EackerExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 1
  • PendingSystems And Methods For Karyotyping By SequencingUSPTOApplication 17442840

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .